Benova Mouth Rinse System Shows Promising Results in Reducing Oral Inflammation

The Benova Mouth Rinse System has emerged as a beacon of hope for individuals suffering from oral mucositis and recurrent aphthous stomatitis, following a study that demonstrated a 17% reduction in the inflammatory marker TNF-alpha within just two minutes of application. This research, presented by Daniel J. Gibson, PhD, at the 2025 Diabetic Limb Salvage Conference, underscores the rinse's potential to alleviate pain and promote healing without the use of lidocaine, steroids, or prescription drugs.

Oral mucositis affects 51% of chemotherapy patients, while recurrent aphthous stomatitis is prevalent in 25% of the general population, making the findings particularly significant. Dr. Gibson's study, conducted at the University of Alabama Capstone College of Nursing, utilized an in vitro model to simulate inflamed oral mucosa, showcasing the rinse's rapid anti-inflammatory effects. 'These results reflect Benova's potential to relieve pain and support healing through targeted cytokine reduction,' Dr. Gibson stated.

Bill Kling, co-founder of Benova, pointed out the alignment between the study's outcomes and anecdotal reports from users who have experienced quick pain relief and healing of oral ulcers. The Diabetic Limb Salvage Conference, renowned for its focus on wound care and tissue regeneration, provided the perfect venue for these findings. The Benova Mouth Rinse System is designed to meet the needs of a broad spectrum of healthcare professionals, including oncologists, dentists, and periodontists, offering immediate relief for conditions like stomatitis and oral mucositis. For more information on the study, visit https://www.example.com.